Photo Credit: iStock.com/Mohammed Haneefa Nizamudeen
Expert consensus underscored the need for coordinated care in SEA with nasal polyps.
A study published in July 2025 issue of Journal of Allergy and Clinical Immunology Global highlighted persistent challenges and fragmented care in managing individuals with severe asthma with an eosinophilic phenotype (SEA) and comorbid chronic rhinosinusitis with nasal polyps (CRSwNP).
Researchers examined current clinical practices and developed recommendations for managing individuals with SEA and comorbid CRSwNP.
They perfomed a 2-round Delphi survey from March to June 2023, developed by a multidisciplinary Scientific Committee (n=11) comprising pulmonologists, allergists, and ear, nose, and throat (ENT) specialists. The survey engaged 205 experts from these 3 specialties across 8 European countries. Consensus was defined as agreement by ≥70% of participants. The survey focused on the initial assessment, treatment, follow-up, and multidisciplinary management of individuals with SEA and CRSwNP.
The results showed that consensus was reached on the importance of evaluating comorbid upper respiratory conditions in individuals with SEA, including CRSwNP [88%], allergic rhinitis [79%], CRSwNP [77%], and aspirin/non-steroidal anti-inflammatory-exacerbated respiratory disease [71%]. A multidisciplinary approach was considered essential across all stages of care—diagnosis [82%], treatment decision-making [83%], and follow-up [79%]. The value of biologics in managing both asthma and CRSwNP symptoms concurrently was supported by 87% of participants.
Investigators concluded that the OverSEA study emphasized the value of assessing upper airway comorbidities, particularly CRSwNP, and underscored the need for multidisciplinary collaboration to improve care for individuals with SEA.
Source: jaci-global.org/article/S2772-8293(25)00130-4/fulltext